{"id":"NCT02803229","sponsor":"New York State Psychiatric Institute","briefTitle":"Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder","officialTitle":"Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-07","primaryCompletion":"2020-06","completion":"2020-06","firstPosted":"2016-06-16","resultsPosted":"2021-04-09","lastUpdate":"2021-04-09"},"enrollment":33,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Cannabis Use Disorder","Attention-deficit/Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"Adderall-XR","otherNames":["Extended-release mixed amphetamine salt"]},{"type":"DRUG","name":"Matched placebo","otherNames":["placebo"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Adderall-XR","type":"EXPERIMENTAL"}],"summary":"The proposed protocol is a double-blind, placebo-controlled outpatient study of the safety and benefit of Extended-release mixed amphetamine salt (Adderall-XR, MAS-XR) in the treatment of individuals with Cannabis Use Disorder (CUD) and Attention-deficit/Hyperactivity Disorder (ADHD). The investigators plan to enroll 50 and randomize 40 of these patients in the trial. The primary objective of the study is to determine the efficacy of MAS-XR in promoting cannabis abstinence among individuals with CUD and in promoting a decrease of ADHD symptoms.","primaryOutcome":{"measure":"Marijuana Abstinence","timeFrame":"Change from baseline compared to last 2 weeks of the 12 week study on maintained dose (weeks 10 and 11 for completers) or last 2 weeks of participants' participation during the study for participants who drop out of the study before weeks 10 and 11","effectByArm":[{"arm":"Placebo","deltaMin":0,"sd":null},{"arm":"Adderall-XR","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":15},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":["insomnia","anxiety","chest pain","headache","nervousness"]}}